Case report of selumetinib as a novel therapy in a neurofibromatosis type 2-associated ependymoma

Case report of selumetinib as a novel therapy in a neurofibromatosis type 2-associated ependymoma

We report partial response (PR) to novel therapy with selumetinib in a patient with neurofibromatosis type 2 (NF2). A 25-year-old male presented with bilateral vestibular schwannomas, spinal cord intramedullary ependymomas, cranial and spinal meningiomas, spinal nerve root mixed schwannoma-neurofibr...

Full description

Bibliographic Details
Main Authors: Nigel Blackwood, Christopher Zetzmann, Christopher R. Trevino
Format: Article
Language:English
Published: Elsevier 2023-12-01
Series:Molecular Therapy: Methods & Clinical Development
Subjects:
neurofibromatosis 2
selumetinib
MEK inhibitor
ependymoma
SMARCB1
Online Access:http://www.sciencedirect.com/science/article/pii/S232905012300195X

Similar Items

Similar Items